Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 18/20 | 0.65 |
| ▸ | DBF4 | Q9UBU7 | 18/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 17/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.65 |
| ▸ | CDK2 | P24941 | 15/20 | 0.65 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614190 | 0.91 | ROCK1 (0.72) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL612582 | 0.87 | CDC7 (0.78) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL613691 | 0.87 | CDC7 (0.60) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL613814 | 0.84 | ROCK1 (0.72) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL612215 | 0.82 | CDC7 (0.57) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL610910 | 0.82 | ROCK1 (0.69) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL613728 | 0.81 | CDC7 (0.56) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL614154 | 0.79 | CDC7 (0.54) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL613653 | 0.79 | ROCK1 (1.00) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL614286 | 0.79 | ROCK1 (0.70) | CDC7DBF4ROCK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691828-B2 | Thienopyrimidine as CDC7 kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-08 | — | — | US | disclosed |
| US-8691828-B2 | Thienopyrimidine as CDC7 kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-08 | — | — | US | disclosed |
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | CDC7 1/4885DBF4 593/4885ROCK1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.